Isabelle L Crary1, Elizabeth U Parker2, Kathryn P Lowry3, Pranav P Patwardhan4, Thing Rinda Soong4, Sara H Javid5, Kristine E Calhoun5, Meghan R Flanagan6,7. 1. University of Washington School of Medicine, Seattle, WA, USA. 2. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. 3. Department of Radiology, University of Washington, Seattle, WA, USA. 4. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 5. Department of Surgery, University of Washington, Seattle, WA, USA. 6. Department of Surgery, University of Washington, Seattle, WA, USA. mrf22@uw.edu. 7. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. mrf22@uw.edu.
Abstract
BACKGROUND: Atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ encompass a spectrum of proliferative lesions known as lobular neoplasia (LN). When imaging-concordant and found in isolation on core needle biopsy (CNB), LN infrequently upgrades to carcinoma on surgical excision, and routine excision is not indicated. Upgrade rates in the setting of synchronous carcinoma are not well studied. PATIENTS AND METHODS: Patients with radiology-pathology concordant synchronous LN and separately biopsied ipsilateral (n = 35) or contralateral (n = 15) carcinoma who underwent excision between 2010 and 2021 were retrospectively identified. Frequency of upgrade, to either invasive or in situ carcinoma, was quantified, and factors associated with upgrade were assessed using Fisher's exact test. RESULTS: The median age was 55 (range 33-74) years. The upgrade rate of LN was 6% and not significantly different between ipsilateral (2.9%) and contralateral (13.3%) carcinoma (p = 0.15). All upgraded LN lesions were ALH on CNB and detected as non-mass enhancement on magnetic resonance imaging (MRI). No additional disease was demonstrated after excision at the site of the original LN CNB in 22.9% (8 out of 35) of ipsilateral and 13.3% (2 out of 15) of contralateral patients. Upgrade was not associated with family history, menopausal status, imaging modality used to detect LN, or extent of LN on CNB (p > 0.05). CONCLUSIONS: Our results demonstrate a low upgrade rate (6%) in our study cohort of LN with synchronous ipsilateral or contralateral carcinoma, which suggests that not all LN mandates excision with synchronous carcinoma. Larger, multi-institution studies are needed to validate these findings.
BACKGROUND: Atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ encompass a spectrum of proliferative lesions known as lobular neoplasia (LN). When imaging-concordant and found in isolation on core needle biopsy (CNB), LN infrequently upgrades to carcinoma on surgical excision, and routine excision is not indicated. Upgrade rates in the setting of synchronous carcinoma are not well studied. PATIENTS AND METHODS: Patients with radiology-pathology concordant synchronous LN and separately biopsied ipsilateral (n = 35) or contralateral (n = 15) carcinoma who underwent excision between 2010 and 2021 were retrospectively identified. Frequency of upgrade, to either invasive or in situ carcinoma, was quantified, and factors associated with upgrade were assessed using Fisher's exact test. RESULTS: The median age was 55 (range 33-74) years. The upgrade rate of LN was 6% and not significantly different between ipsilateral (2.9%) and contralateral (13.3%) carcinoma (p = 0.15). All upgraded LN lesions were ALH on CNB and detected as non-mass enhancement on magnetic resonance imaging (MRI). No additional disease was demonstrated after excision at the site of the original LN CNB in 22.9% (8 out of 35) of ipsilateral and 13.3% (2 out of 15) of contralateral patients. Upgrade was not associated with family history, menopausal status, imaging modality used to detect LN, or extent of LN on CNB (p > 0.05). CONCLUSIONS: Our results demonstrate a low upgrade rate (6%) in our study cohort of LN with synchronous ipsilateral or contralateral carcinoma, which suggests that not all LN mandates excision with synchronous carcinoma. Larger, multi-institution studies are needed to validate these findings.
Authors: Meghan R Flanagan; Mara H Rendi; Kristine E Calhoun; Benjamin O Anderson; Sara H Javid Journal: Ann Surg Oncol Date: 2015-04-17 Impact factor: 5.344
Authors: Mariam N Shehata; Habib Rahbar; Meghan R Flanagan; Mark R Kilgore; Christoph I Lee; Marc D Ryser; Kathryn P Lowry Journal: J Am Coll Radiol Date: 2020-08-27 Impact factor: 5.532
Authors: Miraj G Shah-Khan; Xochiquetzal J Geiger; Carol Reynolds; James W Jakub; Elizabeth R Deperi; Katrina N Glazebrook Journal: Ann Surg Oncol Date: 2012-07-31 Impact factor: 5.344
Authors: Barbara Susnik; Deborah Day; Ellen Abeln; Tara Bowman; Janet Krueger; Karen K Swenson; Michaela L Tsai; Margit L Bretzke; Tamera J Lillemoe Journal: Clin Breast Cancer Date: 2016-06-14 Impact factor: 3.225